BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim HK, Peral C, Rubio-Rodríguez D, Rubio-Terrés C. Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain. Expert Rev Pharmacoecon Outcomes Res 2021;21:315-20. [PMID: 32597317 DOI: 10.1080/14737167.2020.1789457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Megías-vericat J, Bonanad Boix S, Berrueco Moreno R, Mingot-castellano M, Rodríguez López M, Canaro Hirnyk M, Mateo Arranz J, Calvo Villas J, Haya Guaita S, Mesegué Medà M, López Jaime F, Albo-lópez C, Palomero-massanet A, Vilalta Seto N, Leciñena IL, Haro AC, Poveda Andrés J. Pharmacokinetic and clinical improvements after PK-guided switch from standard half-life to extended half-life factor VIII products. Thrombosis Research 2022. [DOI: 10.1016/j.thromres.2022.06.001] [Reference Citation Analysis]
2 Burke T, Asghar S, O'Hara J, Chuang M, Sawyer EK, Li N. Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe. Orphanet J Rare Dis 2021;16:521. [PMID: 34930388 DOI: 10.1186/s13023-021-02152-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Ay C, Feistritzer C, Rettl J, Schuster G, Vavrovsky A, Perschy L, Pabinger I. Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria. Sci Rep 2021;11:12967. [PMID: 34155229 DOI: 10.1038/s41598-021-92245-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]